DSpace Repository

Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru

Show simple item record

dc.contributor.author Boehnke, Kevin F.
dc.contributor.author Valdivieso, Manuel
dc.contributor.author Bussalleu, Alejandro
dc.contributor.author Sexton, Rachael
dc.contributor.author Thompson, Kathryn C.
dc.contributor.author Osorio, Soledad
dc.contributor.author Novoa Reyes, Italo
dc.contributor.author Crowley, John J.
dc.contributor.author Baker, Laurence H.
dc.contributor.author Xi, Chuanwu
dc.date.accessioned 2019-01-25T15:02:17Z
dc.date.available 2019-01-25T15:02:17Z
dc.date.issued 2017
dc.identifier.uri https://hdl.handle.net/20.500.12866/4601
dc.description.abstract OBJECTIVES: Gastric carcinoma is the most common cancer and cause of cancer mortality in Peru. Helicobacter pylori, a bacterium that colonizes the human stomach, is a Group 1 carcinogen due to its causal relationship to gastric carcinoma. While eradication of H. pylori can help prevent gastric cancer, characterizing regional antibiotic resistance patterns is necessary to determine targeted treatment for each region. Thus, we examined primary antibiotic resistance in clinical isolates of H. pylori in Lima, Peru. MATERIALS AND METHODS: H. pylori strains were isolated from gastric biopsies of patients with histologically proven H. pylori infection. Primary antibiotic resistance among isolates was examined using E-test strips. Isolates were examined for the presence of the cagA pathogenicity island and the vacA m1/m2 alleles via polymerase chain reaction. RESULTS: Seventy-six isolates were recovered from gastric biopsies. Clinical isolates showed evidence of antibiotic resistance to 1 (27.6%, n=21/76), 2 (28.9%, n=22/76), or >/=3 antibiotics (40.8%). Of 76 isolates, eight (10.5%) were resistant to amoxicillin and clarithromycin, which are part of the standard triple therapy for H. pylori infection. No trends were seen between the presence of cagA, vacA m1, or vacA m2 and antibiotic resistance. CONCLUSION: The rate of antibiotic resistance among H. pylori isolates in Lima, Peru, is higher than expected and presents cause for concern. To develop more targeted eradication therapies for H. pylori in Peru, more research is needed to better characterize antibiotic resistance among a larger number of clinical isolates prospectively. en_US
dc.language.iso eng
dc.publisher Dove Medical Press
dc.relation.ispartof urn:issn:1178-6973
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Peru en_US
dc.subject amoxicillin en_US
dc.subject antibiotic resistance en_US
dc.subject Helicobacter pylori en_US
dc.title Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.2147/IDR.S123798
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.05

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account